International guidelines

Rest of the world

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update​​[90]

Published by:American Society of Clinical Oncology

Last published:2025

NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate[15]

Published by:National Comprehensive Cancer Network

Last published:2024

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease​​[117]

Published by:European Society for Medical Oncology; European Society of Gynaecological Oncology; European Society of Pathology

Last published:2024

Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment[231]

Published by:National Cancer Institute

Last published:2024

ACR appropriateness criteria: ovarian cancer screening​​[63]

Published by:American College of Radiology

Last published:2024

Ovarian cancer: identifying and managing familial and genetic risk[62]

Published by:National Institute for Health and Care Excellence (UK)

Last published:2024

NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer[17]

Published by:National Comprehensive Cancer Network

Last published:2024

NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal, endometrial, and gastric[14]

Published by:National Comprehensive Cancer Network

Last published:2024

ACR appropriateness criteria: clinically suspected adnexal mass, no acute symptoms​​[81]

Published by:American College of Radiology

Last published:2023

ESMO clinical practice guideline: risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes[16]

Published by:European Society for Medical Oncology

Last published:2023

Newly diagnosed and relapsed epithelial ovarian cancer​​​[88]

Published by:European Society for Medical Oncology

Last published:2023

Ovarian cancer: recognition and initial management[119]

Published by:National Institute for Health and Care Excellence (UK)

Last published:2023

Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update[175]

Published by:American Society of Clinical Oncology

Last published:2022

Germline and somatic tumor testing in epithelial ovarian cancer[77]

Published by:American Society of Clinical Oncology

Last published:2020

BRCA-related cancer: risk assessment, genetic counseling, and genetic testing[76]

Published by:US Preventive Services Task Force

Last published:2019

Committee opinion no. 727. Cascade testing: testing women for known hereditary genetic mutations associated with cancer[78]

Published by:American College of Obstetricians and Gynecologists

Last published:2018 (reaffirmed 2022)

ACR appropriateness criteria: staging and follow-up of ovarian cancer[83]

Published by:American College of Radiology

Last published:2018

Non-epithelial ovarian cancer[118]

Published by:European Society for Medical Oncology

Last published:2018

Practice bulletin no. 182: hereditary breast and ovarian cancer syndrome[13]

Published by:American College of Obstetricians and Gynecologists

Last published:2017 (reaffirmed 2024)

Practice bulletin no. 174: evaluation and management of adnexal masses[79]

Published by:American College of Obstetricians and Gynecologists

Last published:2016 (reaffirmed 2021)

Clinical use of cancer biomarkers in epithelial ovarian cancer[94]

Published by:European Group on Tumor Markers

Last published:2016

Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians[116]

Published by:American College of Physicians

Last published:2014

Use of this content is subject to our disclaimer